170 related articles for article (PubMed ID: 3082756)
21. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.
Schreiber JR; Dahlhauser P
Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644
[TBL] [Abstract][Full Text] [Related]
22. Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.
Pollack M; Pier GB; Prescott RK
Infect Immun; 1984 Feb; 43(2):759-60. PubMed ID: 6420347
[TBL] [Abstract][Full Text] [Related]
23. Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.
Pier GB; Pollack M; Cohen M
Infect Immun; 1984 Aug; 45(2):309-13. PubMed ID: 6430805
[TBL] [Abstract][Full Text] [Related]
24. [Protective artificial polysaccharide-protein antigens made from the O-specific polysaccharides of Pseudomonas aeruginosa bacteria of the immunotypes 1, 2 and 7].
Kul'shin VA; Antsiferova NG; Moroz AF; Dmitriev BA
Zh Mikrobiol Epidemiol Immunobiol; 1988 Nov; (11):69-71. PubMed ID: 2464262
[TBL] [Abstract][Full Text] [Related]
25. Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides.
Cryz SJ; Meadow PM; Fürer E; Germanier R
Eur J Clin Microbiol; 1985 Apr; 4(2):180-5. PubMed ID: 3924605
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
Cryz SJ; Sadoff JC; Cross AS; Fürer E
Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
[No Abstract] [Full Text] [Related]
27. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
Matthews-Greer JM; Gilleland HE
J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.
Pier GB; Thomas DM
J Infect Dis; 1983 Aug; 148(2):206-13. PubMed ID: 6411830
[TBL] [Abstract][Full Text] [Related]
29. Cross-protection by Pseudomonas aeruginosa polysaccharides.
Pier GB
Infect Immun; 1982 Dec; 38(3):1117-22. PubMed ID: 6185423
[TBL] [Abstract][Full Text] [Related]
30. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Sadoff JC; Germanier R
Antibiot Chemother (1971); 1987; 39():249-55. PubMed ID: 3118786
[No Abstract] [Full Text] [Related]
31. Immunochemistry of Pseudomonas aeruginosa lipopolysaccharides and high-molecular-weight polysaccharides.
Pier GB
Rev Infect Dis; 1983; 5 Suppl 5():S950-6. PubMed ID: 6197738
[TBL] [Abstract][Full Text] [Related]
32. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate.
Kashef N; Behzadian-Nejad Q; Najar-Peerayeh S; Mousavi-Hosseini K; Moazzeni M; Djavid GE
J Med Microbiol; 2006 Oct; 55(Pt 10):1441-1446. PubMed ID: 17005795
[TBL] [Abstract][Full Text] [Related]
34. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.
Cryz SJ; Fürer E; Germanier R
Infect Immun; 1984 Mar; 43(3):795-9. PubMed ID: 6698608
[TBL] [Abstract][Full Text] [Related]
35. Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and Immunogenicity.
Najafzadeh F; Shapouri R; Rahnema M; Rokhsartalab Azar S; Kianmehr A
Jundishapur J Microbiol; 2015 Jun; 8(6):e17712. PubMed ID: 26301059
[TBL] [Abstract][Full Text] [Related]
36. Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides.
Lang AB; Fürer E; Schürch U; Cross AS; Larrick JW; Cryz SJ
Dev Biol Stand; 1990; 71():121-6. PubMed ID: 1698165
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
[TBL] [Abstract][Full Text] [Related]
38. Anti-idiotype vaccines for immunity to bacterial polysaccharides: induction of functional antibodies to polysaccharide antigens of Pseudomonas aeruginosa.
Schreiber JR
Springer Semin Immunopathol; 1993; 15(2-3):235-46. PubMed ID: 7504840
[No Abstract] [Full Text] [Related]
39. Characterization of the antibody response in inbred mice to a high-molecular-weight polysaccharide from Pseudomonas aeruginosa immunotype 1.
Markham RB; Pier GB
Infect Immun; 1983 Jul; 41(1):232-6. PubMed ID: 6407998
[TBL] [Abstract][Full Text] [Related]
40. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.
Zollinger WD; Moran EE; Devi SJ; Frasch CE
Infect Immun; 1997 Mar; 65(3):1053-60. PubMed ID: 9038315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
